Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.
2.

Bosentan therapy for pulmonary arterial hypertension.

Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G.

N Engl J Med. 2002 Mar 21;346(12):896-903. Erratum in: N Engl J Med 2002 Apr 18;346(16):1258.

4.

Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.

Ahmadi-Simab K, Hellmich B, Gross WL.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:44-8.

PMID:
16919010
5.

Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension.

Droste AS, Rohde D, Voelkers M, Filusch A, Bruckner T, Borst MM, Katus HA, Meyer FJ.

Respir Res. 2009 Dec 30;10:129. doi: 10.1186/1465-9921-10-129.

6.

First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.

Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:32-8.

PMID:
16919008
8.

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.

Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group.

J Am Coll Cardiol. 2008 Dec 16;52(25):2127-34. doi: 10.1016/j.jacc.2008.08.059.

9.

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.

Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.

Rheumatology (Oxford). 2010 Mar;49(3):490-500. doi: 10.1093/rheumatology/kep398. Epub 2009 Dec 16.

PMID:
20015974
10.

[The efficacy and safety of bosentan therapy for Chinese patients with idiopathic pulmonary arterial hypertension: an open-label, prospective multicenter study].

Dai LZ, Jiang X, Wang Y, Yu ZX, Yao H, Wang GY, Wu BX, Jing ZC; National Bosentan Therapy for PAH Study Group.

Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Feb;39(2):124-7. Chinese.

PMID:
21426745
11.

Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.

Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, Crescenzi E, Nona A, Benedetti G, Ferrante F, Sciomer S, Fedele F.

Regul Pept. 2008 Nov 29;151(1-3):48-53. doi: 10.1016/j.regpep.2008.08.002. Epub 2008 Aug 16.

PMID:
18796317
12.

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.

Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P, Gibbs JS.

Am J Respir Crit Care Med. 2005 Jun 1;171(11):1292-7. Epub 2005 Mar 4.

PMID:
15750042
13.

Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension.

Sasayama S, Kunieda T, Tomoike H, Matsuzaki M, Shirato K, Kuriyama T, Izumi T, Origasa H, Giersbergen PL, Dingemanse J, Tanaka S.

Circ J. 2005 Feb;69(2):131-7. Erratum in: Circ J. 2005 Aug;69(8):1007.

14.

Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease.

Benza RL, Rayburn BK, Tallaj JA, Coffey CS, Pinderski LJ, Pamoukian SV, Bourge RC.

Chest. 2006 Apr;129(4):1009-15.

PMID:
16608951
15.

Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.

Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, Sfriso P, Iliceto S, Todesco S.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:49-53.

PMID:
16919011
16.

Bosentan for patients with chronic thromboembolic pulmonary hypertension.

Vassallo FG, Kodric M, Scarduelli C, Harari S, Potena A, Scarda A, Piattella M, Cassandro R, Confalonieri M.

Eur J Intern Med. 2009 Jan;20(1):24-9. doi: 10.1016/j.ejim.2008.03.008. Epub 2008 Apr 29.

PMID:
19237088
17.

[Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases].

Volkov AV, Iudkina NN, Nikolaeva EV, Kurmukov IA, Glukhova SI, Nasonov EL.

Ter Arkh. 2014;86(5):32-9. Russian.

PMID:
25026800
18.

Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.

Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.

J Heart Lung Transplant. 2012 Feb;31(2):150-8. doi: 10.1016/j.healun.2011.11.002. Epub 2011 Dec 3.

PMID:
22138355
19.

[Effect of bosentan on the clinical status and cellular immunity of patients with idiopathic pulmonary hypertension].

Martyniuk TV, Zykov KA, Antonova OIu, Rvacheva AV, Arkhipova OA, Kobal' EA, Masenko VP, Chazova IE.

Ter Arkh. 2013;85(1):25-31. Russian.

PMID:
23536942
20.

Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.

Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.

Heart. 2007 Mar;93(3):350-4. Epub 2006 Sep 15.

Supplemental Content

Support Center